Bacil Pharma Limited’s Board Approves Rs 50 Crore Fund Raising Proposal
The Board of Directors of Bacil Pharma Limited has approved a proposal to raise up to Rs 50 crores through various permissible modes, following a meeting held on June 26, 2026.During the deliberation, the Board considered and sanctioned the initiative to secure funds for the company up to the maximum amount of Rs 50 crores. The authorized fundraising methods include, but are not limited to, a Rights Issue, Preferential Issue, issuance of convertible securities or warrants, or any other suitable mode or combination thereof.
The Company has also empowered its Managing Director, Chief Financial Officer, Company Secretary, and other designated officials. These officers have been granted authority, either jointly or individually, to evaluate different fund-raising options. They are authorized to appoint intermediaries, undertake necessary due diligence, negotiate the terms and conditions, finalize the structure of the proposed fundraising, and execute all related deeds and actions.
The Board noted that specific aspects of the funding will be determined at a later stage. These include the mode of fundraising, the size of the issue, pricing, class of securities, and associated terms and conditions. These details will be finalized based on management recommendations, prevailing market conditions, and applicable statutory requirements.
Stock Price Movement
Bacil Pharma Ltd settled at ₹39.75 on Thursday, sinking 5.00% in post-market trading. The shares moved through an intraday range that spanned from a low of ₹39.75 to a high of ₹42.39.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.